Pharma BD Deal Intelligence
A patchwork deal: Creon became a durable double-digit grower, but AndroGel collapsed under generic entry, FDA safety warnings, and a $448M antitrust judgment — net a middling-to-poor outcome for the price paid.
Full analysis, sources & comparables →Credit Suisse's Catherine Arnold called the deal underwhelming — TriCor patents expire in two years and Solvay 'does not add long-term growth or reduce…
Abbott closed the acquisition February 16, 2010 for €4.5B cash plus up to €300M in milestones — adding ~$2.9B in 2010 sales (majority ex-US) and a…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott Laboratories acquired Solvay Pharmaceuticals for EUR 5.2B (~$6.6B) plus up to ~$440M in milestones, adding fenofibrate (TriCor/Trilipix), a vaccines business, and emerging-markets presence; closed February 2010.
A patchwork deal: Creon became a durable double-digit grower, but AndroGel collapsed under generic entry, FDA safety warnings, and a $448M antitrust judgment — net a middling-to-poor outcome for the price paid.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Solvay Pharmaceuticals (Solvay Group) (this deal) | 2009 | $6.6B | 51 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2009 deals · Abbott Laboratories deals